# A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

> **NCT07335796** · PHASE2 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 30 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** BMS-986165
- **DRUG:** Degarelix

## Key facts

- **NCT ID:** NCT07335796
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2030-01-09
- **Final completion:** 2030-01-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07335796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07335796, "A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07335796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*